Medpace (MEDP) Expected to Announce Quarterly Earnings on Wednesday

Medpace (NASDAQ:MEDP) is expected to be posting its Q1 2026 results after the market closes on Wednesday, April 22nd. Analysts expect Medpace to post earnings of $3.74 per share and revenue of $697.8220 million for the quarter. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, April 23, 2026 at 9:00 AM ET.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating the consensus estimate of $4.18 by $0.49. The company had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm’s quarterly revenue was up 32.0% compared to the same quarter last year. During the same quarter last year, the firm earned $3.67 EPS. On average, analysts expect Medpace to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Medpace Price Performance

Medpace stock opened at $520.60 on Monday. The firm has a fifty day simple moving average of $468.38 and a two-hundred day simple moving average of $537.94. Medpace has a twelve month low of $250.05 and a twelve month high of $628.92. The company has a market capitalization of $14.87 billion, a PE ratio of 34.03, a P/E/G ratio of 2.50 and a beta of 1.39.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective on the stock in a research note on Friday, February 13th. BMO Capital Markets restated a “market perform” rating on shares of Medpace in a report on Wednesday, February 11th. Truist Financial reduced their price target on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. TD Cowen raised Medpace from a “sell” rating to a “hold” rating and decreased their price target for the stock from $462.00 to $419.00 in a research note on Wednesday, February 18th. Finally, Zacks Research downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Medpace has a consensus rating of “Hold” and an average price target of $486.67.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Market/technical note: Medpace’s relative strength rating reportedly rose to 82, a signal some traders use to justify momentum buying. Stocks to watch: Medpace Holdings sees relative strength rating rise to 82
• Neutral Sentiment: Procedural deadline reminder: Several firms (e.g., Faruqi & Faruqi) remind investors there’s a June 8, 2026 deadline to seek lead‑plaintiff status — procedural notices that maintain public attention but don’t by themselves change fundamentals. MEDP INVESTOR DEADLINE APPROACHING
• Negative Sentiment: New class‑action filing/solicitation: Bronstein, Gewirtz & Grossman says a class action has been filed against Medpace and certain officers covering Apr 22, 2025–Feb 9, 2026 — this is the primary legal catalyst investors will watch. Bronstein class action notice
• Negative Sentiment: Multiple law firms seek clients/lead‑plaintiff roles (Robbins Geller, Gross Law Firm, Bragar Eagel & Squire, Rosen, Pomerantz, Frank R. Cruz, SueWallSt, Rosen/others) — this concentrated legal publicity increases the chance of follow‑on litigation costs and management distraction. Example: Robbins Geller urges investors to act. Robbins Geller investor alert
• Negative Sentiment: Additional firm notices and press pieces (Gross Law Firm, Bragar Eagel & Squire, Rosen Law Firm, Frank R. Cruz, Pomerantz, SueWallSt) further amplify the claims and the investor outreach, keeping the stock under legal/PR pressure. Example: Gross Law Firm alert. Gross Law Firm alert
• Negative Sentiment: Local/regional coverage highlights plaintiff‑opportunity: Bakersfield and other outlets reiterate the chance for investors to lead the suit, sustaining media attention on the litigation risk. Bakersfield/AP coverage

Insider Activity at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the sale, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Medpace

Several institutional investors and hedge funds have recently bought and sold shares of MEDP. Geneos Wealth Management Inc. grew its position in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the last quarter. Quarry LP purchased a new stake in Medpace in the third quarter worth $35,000. Greenline Wealth Management LLC purchased a new position in Medpace during the 4th quarter valued at $55,000. Group One Trading LLC increased its position in Medpace by 120.0% during the 4th quarter. Group One Trading LLC now owns 100 shares of the company’s stock valued at $56,000 after purchasing an additional 600 shares during the period. Finally, Johnson Financial Group Inc. raised its holdings in Medpace by 115.7% in the 3rd quarter. Johnson Financial Group Inc. now owns 110 shares of the company’s stock worth $57,000 after purchasing an additional 59 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.